The World Health Organization declared as a particularly dangerous infections of international importance 3 diseases: plague, cholera (since 1980 from the list excluded smallpox) and yellow fever (and similar to her Ebola and Marburg). In Russia, the list is supplemented with tularemia and anthrax.

The genus Ebolavirus is a virological taxon included in the family Filoviridae, order Mononegavirales. The members of this genus are called ebolaviruses. The five known virus species are named for the region where each was originally identified: Bundibugyo ebolavirus, Reston ebolavirus, Sudan ebolavirus, Taï Forest ebolavirus, and Zaire ebolavirus.

Ebolaviruses were first described after outbreaks of EVD in southern Sudan in June 1976 and in Zaire in August 1976.

Researchers have now found evidence of Ebola infection in three species of fruit bat. The bats show no symptoms of the disease, indicating that they may be natural reservoirs of the Ebolavirus.

Zaire ebolavirus (ZEBOV) 

ZEBOV has the highest case-fatality rate, up to 90% in some epidemics, with an average case fatality rate of approximately 83% over 27 years.

Sudan ebolavirus (SUDV) 

SUDV emerged in 1976. SUDV is believed to have broken out first amongst cotton factory workers in Nzara, Sudan (now in South Sudan), in June 1976, with the first case reported as a worker exposed to a potential natural reservoir.

Reston ebolavirus (RESTV) 

This virus was discovered during an outbreak of simian hemorrhagic fever virus (SHFV) in crab-eating macaques in 1989.  Despite its status as a Level'4 organism and its apparent pathogenicity in monkeys, RESTV did not cause disease in exposed human laboratory workers.

Taï Forest ebolavirus (TAFV)

It was first discovered among chimpanzees from the Tai Forest in Côte d'Ivoire, Africa, in 1994.

Bundibugyo ebolavirus (BDBV)

On November 24, 2007, the Uganda Ministry of Health confirmed an outbreak of Ebola in the Bundibugyo District.


Treatment is only symptomatic: rehydration with electrolyte solutions.

Currently, no vaccine against Ebola exist. Nearly 10 years ago its development involved the United States and Canada (Texas Medical University, Vanderbilt University), but because of unprofitability project was stopped at the stage of animal experiments. Up to 2014 the number of cases of Ebola did not reach the hundreds per year, and the virus spread in countries with low pay, while at the development of a vaccine required hundreds of millions of dollars.

As promising drugs for Ebola, WHO considers vaccines VSV-EBOV (Canada Winnipeg, Manitoba) and ChAd-EBO (developed by the British company GlaxoSmithKline), based on the vesicular stomatitis virus in which a gene introduced Ebola and chimpanzee adenovirus.

Russian Ebola vaccine developed by the Novosibirsk State Scientific Center of Virology and Biotechnology "Vector".

WHO and international medical organizations provide humanitarian supplies to countries affected by the epidemic. Among other things, they were purchased biological protection means EGO Zlín. In particular, the company has developed a unique bio-isolators for the transportation of infected patients and protective transport bag for infected patient.

WestMedGroup Company for several years engaged in supplying of biological and chemical protection - isolation box for infected patient Biobox for infectious diseases and protective transport bag for infected patient Biobag.                                                                                         

Protective transport bag for infected patient Biovak EBV-40 / EBVT-30 is fairly spacious insulators on a mobile stretcher to transport a person suspected of being infected with the most dangerous infections. Large viewing window of protective transport bag for infected patient allow constant monitoring, a variety of ports adapted for all types of medical equipment. Equipment can operate autonomously for 8 hours.